CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc. is a leading non-clinical global drug development partner with a mission to create healthier lives. The company has been in operation since 1947 and was incorporated in 1994. Its stock is traded on the New York Stock Exchange under the symbol "CRL." The company is headquartered in Wilmington, Massachusetts, and its website is www.criver.com. Charles River provides a diverse portfolio of products and services that support the drug discovery and development process, from research models and services to discovery and safety assessment, and manufacturing solutions. Its research models and services include the production and sale of research models, research model services, and cell solutions. Its discovery and safety assessment services include discovery services and safety assessment. Its manufacturing solutions include microbial solutions and biologics solutions. The company's business strategy is to leverage its leading portfolio in non-clinical drug research to aid clients in bringing their drugs to market faster. Its client base includes major global pharmaceutical companies, biotechnology companies, and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world. In 2023, the company had total revenue of $4.1 billion and approximately 21,700 employees. The company's reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing. RMS is comprised of three businesses: Research Models, Research Model Services, and Cell Solutions. DSA is comprised of Discovery Services and Safety Assessment. Manufacturing is comprised of Microbial Solutions and Biologics Solutions. The Research Models business provides the most widely used small research models, primarily rodents, for use in drug discovery and development. The Research Model Services business offers flexible solutions designed to support clients' use of research models in basic research and screening pre-clinical drug candidates. The Cell Solutions business provides consenting human donor-derived cellular materials used in the development and production of cell therapies. The Discovery Services business operates as a single source of services for discovering and characterizing novel drug candidates for preclinical development. It offers a full spectrum of discovery services from target discovery and validation to delivery of preclinical drug and therapeutic candidates ready for safety assessment. The Safety Assessment business offers a full range of safety assessment studies required for regulatory submission on a global basis across all therapeutic areas. The Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. Microbial Solutions provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. Biologics Solutions includes Biologics Testing Solutions and CDMO business. Biologics Testing Solutions provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies. The CDMO business provides comprehensive contract development and manufacturing solutions for cell and gene therapies.